Asunto(s)
Embolización Terapéutica , Próstata , Prostatectomía , Hiperplasia Prostática , Urodinámica , Humanos , Prostatectomía/métodos , Masculino , Próstata/irrigación sanguínea , Próstata/patología , Embolización Terapéutica/métodos , Hiperplasia Prostática/cirugía , Hiperplasia Prostática/terapia , Hiperplasia Prostática/complicaciones , Ensayos Clínicos Controlados Aleatorios como Asunto , Tamaño de los ÓrganosRESUMEN
Lymphatic filarial (LF) parasites have been under anti-filarial drug pressure for more than half a century. Currently, annual mass drug administration (MDA) of diethylcarbamazine (DEC) or ivermectin in combination with albendazole (ALB) have been used globally to eliminate LF. Long-term chemotherapies exert significant pressure on the genetic structure of parasitic populations. We investigated the genetic variation among 210 Wuchereria bancrofti populations that were under three different chemotherapy strategies, namely MDA with DEC alone (group I, n = 74), MDA with DEC and ALB (group II, n = 60) and selective therapy (ST) with DEC (group III, n = 34) to understand the impact of these three drug regimens on the parasite genetic structure. Randomly amplified polymorphic DNA profiles were generated for the three groups of parasite populations; the gene diversity, gene flow and genetic distance values were determined and phylogenetic trees were constructed. Analysis of these parameters indicated that parasite populations under ST with a standard dose of DEC (group III) were genetically more diverse (0.2660) than parasite populations under MDA with DEC alone (group I, H = 0.2197) or with DEC + ALB (group II, H = 0.2317). These results indicate that the MDA may reduce the genetic diversity of W. bancrofti populations when compared to the genetic diversity of parasite populations under ST.
Asunto(s)
Albendazol/administración & dosificación , Dietilcarbamazina/administración & dosificación , Filaricidas/administración & dosificación , Variación Genética/efectos de los fármacos , Ivermectina/administración & dosificación , Wuchereria bancrofti/efectos de los fármacos , Animales , Esquema de Medicación , Quimioterapia Combinada , Filariasis Linfática/tratamiento farmacológico , Filariasis Linfática/parasitología , Humanos , Técnica del ADN Polimorfo Amplificado Aleatorio , Wuchereria bancrofti/genéticaRESUMEN
Lymphatic filarial (LF) parasites have been under anti-filarial drug pressure for more than half a century. Currently, annual mass drug administration (MDA) of diethylcarbamazine (DEC) or ivermectin in combination with albendazole (ALB) have been used globally to eliminate LF. Long-term chemotherapies exert significant pressure on the genetic structure of parasitic populations. We investigated the genetic variation among 210 Wuchereria bancrofti populations that were under three different chemotherapy strategies, namely MDA with DEC alone (group I, n = 74), MDA with DEC and ALB (group II, n = 60) and selective therapy (ST) with DEC (group III, n = 34) to understand the impact of these three drug regimens on the parasite genetic structure. Randomly amplified polymorphic DNA profiles were generated for the three groups of parasite populations; the gene diversity, gene flow and genetic distance values were determined and phylogenetic trees were constructed. Analysis of these parameters indicated that parasite populations under ST with a standard dose of DEC (group III) were genetically more diverse (0.2660) than parasite populations under MDA with DEC alone (group I, H = 0.2197) or with DEC + ALB (group II, H = 0.2317). These results indicate that the MDA may reduce the genetic diversity of W. bancrofti populations when compared to the genetic diversity of parasite populations under ST.